THE CHALLENGE

THE CHALLENGE

Only 5th largest spend on cancer specific site

Prostate cancer is the most common male cancer, and advanced prostate cancer has no cure. Whilst prostate cancer is treatable when localised within the prostate, it becomes life-limiting and potentially terminal when cancerous cells spread around the body. There is an urgent need to develop novel and effective treatments for men with advanced prostate cancer, as this is when it kills. However, the funding for advanced prostate cancer is limited and decreasing. In the UK, we spent £22.7m on prostate cancer research in 2017/18. This makes it only the 5th largest spend on a specific cancer site 1, despite the fact that prostate cancer is ranked the 2nd most common cause of cancer death in men in the UK in the UK 2. And, together treatment and early detection, diagnosis and prognosis receive more than 70% of the money funding prostate cancer research in the UK 3 .

The addition of £2,300,000 – the value of our recent grant call – constitutes a 10% rise in the amount of money spent on prostate cancer research in the UK.